Predicted Trait | |
Reported Trait | Breast cancer |
Mapped Trait(s) | breast carcinoma (EFO_0000305) |
Score Construction | |
PGS Name | PRS67 |
Development Method | |
Name | Hard thresholding |
Parameters | 41 SNPs were identified with P<5xE-08 and additional 26 SNPs were further identified through familiar risk fitted disctribution of z scores in those SNPs that did not have associations reaching genome-wide levels of significance [ refer to Overall contribution to breast cancer susceptibility section of reference 8, Michailidou et al 2014] |
Variants | |
Original Genome Build | NR |
Number of Variants | 67 |
Effect Weight Type | NR |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000036 |
Citation (link to publication) | Zhang X et al. PLoS Med (2018) |
Ancestry Distribution | |
Source of Variant Associations (GWAS) | European: 100% 22,627 individuals (100%) |
PGS Evaluation |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
---|---|---|---|
GWAS Catalog: GCST001937 Europe PMC: 23535729 |
22,627 individuals | European | NR |
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM000128 | PSS000080| Multi-ancestry (including European)| 11,880 individuals |
PGP000036 | Zhang X et al. PLoS Med (2018) |
Reported Trait: Invasive breast cancer | — | AUROC: 0.65 [0.64, 0.66] | — | Gail BC risk model, Mammographic density (MD), Testoterone (T), estrone sulfate (E1S), prolactin (PRL) | Age-adjusted AUC |
PPM000130 | PSS000080| Multi-ancestry (including European)| 11,880 individuals |
PGP000036 | Zhang X et al. PLoS Med (2018) |
Reported Trait: Invasive breast cancer | — | — | Relative Risk (RR; higest vs. lowest quartile PRS): 2.5 [2.2, 2.8] | Demographics and parameters of baseline blood draw (age, BMI, fasting status, time of day, season), history of benign breast disease, family history of breast cancer, age at menopause, age at menarche, physical activity, age at first birth and parity | — |
PPM000129 | PSS000081| Multi-ancestry (including European)| 8,160 individuals |
PGP000036 | Zhang X et al. PLoS Med (2018) |
Reported Trait: Invasive breast cancer | — | AUROC: 0.678 [0.666, 0.69] | — | Rosner-Colditz BC risk model, Mammographic density (MD), Testoterone (T), estrone sulfate (E1S), prolactin (PRL) | Age-adjusted AUC |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS000080 | Questionnaires were mailed to women biennially to collect information on breast cancer risk factors, including age at menarche, age at first birth, parity, family history of breast cancer, height, weight, physical activity, menopausal status, age at menopause, and HT use. Incident breast cancer cases up to 1 June 2010 were also identified through biennial questionnaires. Diagnoses were confirmed with the participants (or next of kin), and permission was obtained to collect relevant medical or pathology reports. Analysis was restricted to invasive breast cancer. | Mean = 26.54 years | [ ,
0.0 % Male samples |
Mean = 53.7 years Sd = 8.0 years Range = [34.0, 70.0] years |
European, NR | — | NHS, NHS2 | Performance metrics are reported for the "All women" results of Table 2 |
PSS000081 | Questionnaires were mailed to women biennially to collect information on breast cancer risk factors, including age at menarche, age at first birth, parity, family history of breast cancer, height, weight, physical activity, menopausal status, age at menopause, and HT use. Incident breast cancer cases up to 1 June 2010 were also identified through biennial questionnaires. Diagnoses were confirmed with the participants (or next of kin), and permission was obtained to collect relevant medical or pathology reports. Analysis was restricted to invasive breast cancer. | Mean = 23.08 years | [ ,
0.0 % Male samples |
Mean = 53.7 years Sd = 8.0 years Range = [34.0, 70.0] years |
European, NR | — | NHS, NHS2 | Performance metrics are reported for the "All women" results of Table 3 |